ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals

ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals - completes radiant phase 2 enrollment; topline results expected September-october 2026 - Begins screening and enrollment for phase 3 studies of remlifanserin